“Avosentan reduces albuminuria when added to standard treatment in people with Type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure,” the study authors write. “Of particular concern was a trend to a higher mortality with avosentan….
Read More »Normal Glucose Greater than 85mg/dL in Kids Predicts Diabetes Later
Increases in fasting plasma glucose during childhood — even though levels remain in the normal range 85-100mg/dL.) — can predict adult prediabetes and Type 2 diabetes later in life, a retrospective cohort study showed.…
Read More »Genetic Predeterminants Identified for Diabetes in African-Americans
Inherited genetic variations exist between whites and blacks living in the U.S., leading to less efficient metabolism of glucose and predisposition to diabetes in blacks.
Read More »Olmesartan (Benicar®) Helps Prevent Microalbuminuria in Early Diabetes
Olmesartan reduced the risk of microalbuminuria by 23% in normoalbuminuric patients with Type 2 diabetes and at least one additional cardiovascular disease risk factor, results from a large European trial showed.
Read More »Diabetic Medications and Exercise, Part 1: Oral Medications
Sheri Colberg, Ph.D., FACSM, has been helping patients with diabetes successfully increase physical activity for many years and has written numerous books that patients and clinicians use. Most of her work recently has been about insulin and exercise, but many of you have written me to ask, “What about oral …
Read More »Can Tight Glucose Control Increase Mortality in Critically Ill Patients?
The study showed that “intensively lowering blood glucose to a target of 81 to 108 mg/dL does not benefit critically ill patients and may well increase their risk of…
Read More »Metabolic Syndrome More Common in Type 2 Vs. Autoimmune Diabetes
The prevalence of metabolic syndrome is significantly higher in patients with type 2 diabetes than in those with autoimmune diabetes.
Read More »Reducing Heart Rate in Hypertension Is Harmful – or Is It Just Atenolol?
Slowing the heart rate with beta blockers in people with hypertension is associated with an increased risk of cardiovascular events and death, a new systematic review shows]. Furthermore, the slower the heart rate, the greater the risk.
Read More »Fenofibrate Combo Helps Curb Heart Problems in Diabetics
Fenofibrate in combination with coenzyme Q10 (CoQ) appears to have a number of beneficial effects in type 2 diabetic subjects with mild left ventricular (LV) diastolic dysfunction, researchers report.
Read More »Newly Diagnosed Type 2’s Show Signs of Macrovascular Disease
Study concludes that newly diagnosed never treated patients with type 2 diabetes without any cardiovascular risk factors show early manifestations of macrovascular disease.
Read More »